Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 9/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 5/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL743622 | 0.91 | HTR6 (0.41) | HTR6HTR3ADRD2HTR2C | |
| SCHEMBL741642 | 0.83 | HTR6 (0.42) | HTR6HTR3AHTR2CMEN1KMT2A | |
| SCHEMBL743928 | 0.81 | HTR6 (0.39) | HTR6HTR3ADRD2HTR2C | |
| Trifluoroacetic Acid SCHEMBL742378 | 0.81 | HTR6 (0.36) | HTR6HTR3ADRD2HTR2CMEN1 | |
| SCHEMBL743592 | 0.76 | HTR6 (0.45) | HTR6HTR3AHTR2CMEN1KMT2A | |
| SCHEMBL741603 | 0.75 | HTR6 (0.42) | HTR6HTR3AHTR2C | |
| Trifluoroacetic Acid SCHEMBL742632 | 0.71 | HTR6 (0.37) | HTR6HTR3AHTR2CMEN1KMT2A | |
| SCHEMBL2793111 | 0.68 | DRD2 (0.48) | DRD2 | |
| SCHEMBL741113 | 0.68 | HTR6 (0.42) | HTR6HTR3ADRD2HTR2C | |
| SCHEMBL742369 | 0.67 | HTR6 (0.43) | HTR6HTR3ADRD2HTR2CLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138333-B2 | Sulfonyl-indole derivatives | PROXIMAGEN LIMITED (GB) | 2012-03-20 | — | — | US | disclosed |
| US-20080293694-A1 | New compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293694-A1 | New compounds | HTR6, HTR1A, HTR1B | HTR6 1/4885HTR3A 12/4885DRD2 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.